These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10201514)

  • 1. Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer.
    Johnson D; Tonato M
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):1-2. PubMed ID: 10201514
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
    Ngeow J; Toh CK
    Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
    Bunn PA
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):17-22. PubMed ID: 12094334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, pemetrexed, and novel agents in the treatment of thoracic cancer. Selected presentations from the 10th World Congress on Lung Cancer. Vancouver, Canada.
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):5-71. PubMed ID: 15675032
    [No Abstract]   [Full Text] [Related]  

  • 5. ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer.
    Novello S; le Chevalier T
    Lung Cancer; 2001 Dec; 34 Suppl 4():S107-9. PubMed ID: 11742713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
    Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.
    De Pas TM; Toffalorio F; Catania C; Noberasco C; Spitaleri G; Spaggiari L; De Braud F
    Ann Oncol; 2009 Oct; 20(10):1747-8. PubMed ID: 19690055
    [No Abstract]   [Full Text] [Related]  

  • 9. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
    Cohen MH; Justice R; Pazdur R
    Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of MTA in the treatment of non-small cell lung cancer.
    Postmus PE; Green MR
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
    Blakely LJ; Schwartzberg L; Keaton M; Schnell F; Henry D; Epperson A; Walker MS
    Lung Cancer; 2009 Oct; 66(1):97-102. PubMed ID: 19167130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gemcitabine and pemetrexed in genito-urinary tumors treatment].
    Fléchon A
    Bull Cancer; 2007; 94 Spec No Actualites():S116-21. PubMed ID: 17845980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
    Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies of pemetrexed and gemcitabine combinations.
    Adjei AA
    Ann Oncol; 2006 May; 17 Suppl 5():v29-32. PubMed ID: 16807459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and Pemetrexed disodium in treating breast cancer.
    Adjei AA
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):34-7. PubMed ID: 11252887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed in the treatment of non-small cell lung cancer.
    Shepherd FA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 19. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
    Adjei AA
    Lung Cancer; 2001 Dec; 34 Suppl 4():S103-5. PubMed ID: 11742712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Kotsakis A; Hatzidaki D; Vamvakas L; Vardakis N; Kalykaki A; Bozionelou V; Androulakis N; Kalbakis K; Saridaki Z; Georgoulias V; Agelaki S
    Anticancer Res; 2010 Oct; 30(10):4335-42. PubMed ID: 21036760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.